Is FDG maximum standardized uptake value of primary breast cancer a prognostic factor for locoregional axillary lymph node metastasis?

Is FDG maximum standardized uptake value of primary breast cancer a prognostic factor for locoregional axillary lymph node metastasis? Acta Radiol. 2019 Feb 04;:284185118824770 Authors: Refaat R, Abd Alkhalik Basha M, Sobhi Hassan M, Hussein RS, Al-Molla RM, Awad NM, Elkholy E Abstract BACKGROUND: 18F-fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) has been widely used for diagnosis and staging of disease recurrence in breast cancer patients. PURPOSE: To determine the validity of 18F-FDG PET/CT maximum standardized uptake value (SUVmax) of primary breast cancer (SUVmax-T) as a prognostic factor for locoregional axillary lymph node metastasis (ALNM). MATERIAL AND METHODS: We prospectively studied 198 female patients with pathologically proven breast cancer. All patients were submitted to 18F-FDG PET/CT imaging for their initial tumor staging. The SUVmax-T on 18F-FDG PET/CT and ALNM were assessed. The patients were categorized into two groups; group A, with ALNM, and group B, without ALNM, according to the presence of locoregional ALNM on visual analysis of 18F-FDG PET/CT. The correlations and differences between two groups were statistically evaluated. The optimal cut-off value of SUVmax-T was determined. RESULTS: The mean tumor size in group A was significantly greater than that in group B ( P = 0.0416). The mean SUVmax-T value in group A was significantly higher than that in group...
Source: Acta Radiologica - Category: Radiology Authors: Tags: Acta Radiol Source Type: research

Related Links:

CONCLUSION: Application of the subtype-guided 18F-FDG PET/CT could accurately predict nodal response and aid in tailoring axillary surgery among patients with node-positive breast cancer after NAC, which includes identifying candidates appropriate for TAD or directly proceeding to ALND. This approach might help to avoid false-negative events in TAD. IMPLICATIONS FOR PRACTICE: This feasibility study showed that 18[F]-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) could accurately predict nodal response after neoadjuvant chemotherapy (NAC) among patients with breast cancer with in...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
ConclusionsMTV, a volumetric parameter of FDG PET/CT, is an important independent prognostic factor for PFS to the first line palliative treatment, irrespective of tumor subtype, in patients with MBC.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureY.H. Park: Advisory / Consultancy, Research grant / Funding (self): AstraZeneca; Advisory / Consultancy, Research grant / Funding (self): Pfizer; Advisory / Consultancy, Research grant / Funding (self): Eisai; Advisory / Consultancy, Research grant / Funding (self): Novartis; Research grant / Funding (self): Roche. All other authors...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
AbstractBackgroundThe density of tumor-infiltrating lymphocytes (TIL) is a predictive factor for response to neoadjuvant systemic therapy (NAST) in breast cancer. High TIL density correlates with higher complete pathologic remission (pCR) in triple negative and HER2 positive breast cancer. Additionally, not only TIL density but also subsets of immune cells in tumor stroma seem to play an important role in cancer and immune cell interaction and response to chemotherapy. Our aim is to determine TIL density and expression of CD 20, CD3, CD8, PD-L1, FOXP3 and PGM1 on core biopsy specimen and find a correlation with pCR.Trial d...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionDespite guideline recommendations, a high rate of preoperative staging imaging is completed for patients with clinical stage 1 or 2 breast cancer who receive NAC, with few positive results.
Source: Annals of Surgical Oncology - Category: Cancer & Oncology Source Type: research
Conclusion: Glutathione-S-Transferase P1 Promotor methylation plays a role in breast cancer development. PMID: 31450928 [PubMed - in process]
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research
Late recurrence of estrogen receptor (ER) positive breast cancer is common. When tissues from a recurrent or metastatic focus are available, re-evaluation of ER, progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2) status is recommended for treatment selection. This case report describes a 59-year-old woman who underwent surgery for left breast cancer, with a histopathological diagnosis of invasive ductal carcinoma (pathological stage T2N1aM0 Stage IIB, ER positive, PgR positive and HER2 negative). A health check-up 16 years after surgery revealed multiple hepatic mass lesions, and the patient w...
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
Conclusions: Targeting the GRPR and integrin αvβ3 for nuclear imaging and/or treatment might have the potential to improve BC care in primary as well as metastatic disease.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Breast Cancer Posters Source Type: research
Conclusions: The newly developed radiomic signature was a powerful predictor of LN metastasis and the radiomics nomogram could facilitate the preoperative individualized prediction of LN status. Introduction Gastric cancer (GC) is one of the most common malignant tumors and the second leading cause of cancer-related deaths worldwide (1). Accurate evaluation of lymph node metastasis (LNM) status in GC patients is vital for prognosis and treatment decisions (2–4). Some histopathologic factors and biomarkers (e.g., lymphatic invasion, matrix metalloproteinase-2) are found to be able to predict LNM in GC, but mos...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSIONSFor patients with Luminal/HER2 negative breast cancer, the combination of the imaging features of the tumor and the mammary gland, obtained with 18F-FDG PET-CT at baseline and after the first cycle of NAC, may allow the physician to evaluate the probability of BCS.
Source: European Journal of Radiology - Category: Radiology Source Type: research
Abstract PURPOSE: Predictive biomarkers to identify patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer who may benefit from targeted therapy alone are required. We hypothesized that early measurements of tumor maximum standardized uptake values corrected for lean body mass (SULmax) on [18F]fluorodeoxyglucose positron emission tomography/computed tomography would predict pathologic complete response (pCR) to neoadjuvant pertuzumab and trastuzumab (PT). PATIENTS AND METHODS: Patients with stage II/III, estrogen receptor-negative, HER2-positive breast cancer received four cycles...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: J Clin Oncol Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | CT Scan | HER2 | PET Scan | Radiology | Statistics